Company intelligence / Profile preview

CytoAstra

Little Rock, Arkansas, United Statescytoastra.com ↗

Ownership: Private
Development stage: Other

Overview

CytoAstra has completed a successful pilot study in melanoma patients using its Cytophone platform. The technology is protected by three issued patents and one pending. It offers highly sensitive, noninvasive detection of rare abnormal cells in the bloodstream, with up to 10,000-fold sensitivity improvement over existing methods. Early feasibility studies have been supported by NIH grants; further development is needed for commercial prototypes and comprehensive clinical trials

Therapeutic areas: Infectious DiseasesCardiovascularOncology
Modalities: DeviceNanoparticle (as photoacoustic agents)
Industry: Medical Imaging

Partnerships

University of Arkansas for Medical Sciences (UAMS) subaward partner on NIH grant-funded research project

Beyond the preview

Go deeper on CytoAstra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoAstra.

Explore the full profile